Long-term Efficacy of Intravenous Immunoglobulin Therapy for Moderate to Severe Childhood Atopic Dermatitis.
- Author:
Sue Jung JEE
1
;
Joo Hwa KIM
;
Hey Sung BAEK
;
Ha Baik LEE
;
Jae Won OH
Author Information
- Publication Type:Original Article ; Clinical Trial ; Randomized Controlled Trial
- Keywords: Intravenous immunoglobulin; atopic dermatitis
- MeSH: Cell Adhesion; Child; Dermatitis, Atopic; Eosinophils; Humans; Immunization, Passive; Immunoglobulin E; Immunoglobulins; Immunoglobulins, Intravenous; Interleukins; Mass Screening; Prospective Studies; Th2 Cells
- From:Allergy, Asthma & Immunology Research 2011;3(2):89-95
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The present study investigates the long-term effects of intravenous immunoglobulin (IVIg) therapy for the treatment of moderate to severe childhood atopic dermatitis (AD). Previous research indicates that IVIg can treat severe AD; however, the effectiveness of IVIg has not been confirmed in prospective, blinded clinical trials. METHODS: Forty eligible children with moderate to severe AD, as defined by the criteria of Hanifin and Rajka, were enrolled in a randomized, placebo-controlled study. After the completion of an initial screening visit (V0), the patients were randomly allocated into therapy (n=30) and control (n=10) groups (V1). Thirty children were each treated with three injections of 2.0 g/kg IVIg at 1-month intervals over a 12-week period. Ten children were treated with placebo. Assessments were conducted after each injection (V2, V3, and V4) and at 3 (V5) and 6 months (V6) after completed treatment. RESULTS: The disease severity index was significantly decreased at V5 compared with the value at V1 (P<0.05). There were no significant changes in the total IgE level or total eosinophil count in peripheral blood at the last injection (V4) compared with the value at V1. The interleukin (IL)-5/interferon (IFN)-gamma ratio was assessed in T-helper 1 (Th1) and Th2 cells. The ratio significantly decreased between V1 and V5, after which it increased, such that the ratio at V6 was not significantly different from that at V1. Compared with the level at V1, the intercellular cell adhesion molecule-1 level at V4 did not differ significantly, but the level at V5 was lower. CONCLUSIONS: This study suggests that IVIg therapy may clinically improve AD in patients after 3 months of therapy, but the improvement may decline by 6 months after therapy.
